ES2615265T3 - Métodos para determinar la probabilidad de supervivencia y para predecir la probabilidad de metástasis en el cáncer - Google Patents

Métodos para determinar la probabilidad de supervivencia y para predecir la probabilidad de metástasis en el cáncer Download PDF

Info

Publication number
ES2615265T3
ES2615265T3 ES12785543.5T ES12785543T ES2615265T3 ES 2615265 T3 ES2615265 T3 ES 2615265T3 ES 12785543 T ES12785543 T ES 12785543T ES 2615265 T3 ES2615265 T3 ES 2615265T3
Authority
ES
Spain
Prior art keywords
her2
subject
cancer
protein
limit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12785543.5T
Other languages
English (en)
Spanish (es)
Inventor
Weidong Huang
Jodi WEIDLER
Jeff Sperinde
Mojgan HADDAD
Michael Bates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Labcorp Holdings Inc
Original Assignee
Laboratory Corp of America Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratory Corp of America Holdings filed Critical Laboratory Corp of America Holdings
Application granted granted Critical
Publication of ES2615265T3 publication Critical patent/ES2615265T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES12785543.5T 2011-05-19 2012-05-21 Métodos para determinar la probabilidad de supervivencia y para predecir la probabilidad de metástasis en el cáncer Active ES2615265T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161488028P 2011-05-19 2011-05-19
US201161488028P 2011-05-19
PCT/US2012/038867 WO2012159115A1 (en) 2011-05-19 2012-05-21 Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients

Publications (1)

Publication Number Publication Date
ES2615265T3 true ES2615265T3 (es) 2017-06-06

Family

ID=47175183

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12785543.5T Active ES2615265T3 (es) 2011-05-19 2012-05-21 Métodos para determinar la probabilidad de supervivencia y para predecir la probabilidad de metástasis en el cáncer
ES16189315T Active ES2701929T3 (es) 2011-05-19 2012-05-21 Métodos para determinar la probabilidad de supervivencia y para predecir la probabilidad de metástasis en el cáncer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16189315T Active ES2701929T3 (es) 2011-05-19 2012-05-21 Métodos para determinar la probabilidad de supervivencia y para predecir la probabilidad de metástasis en el cáncer

Country Status (7)

Country Link
US (2) US20120295259A1 (cg-RX-API-DMAC7.html)
EP (2) EP3124975B1 (cg-RX-API-DMAC7.html)
JP (2) JP6468838B2 (cg-RX-API-DMAC7.html)
CA (1) CA2835284C (cg-RX-API-DMAC7.html)
ES (2) ES2615265T3 (cg-RX-API-DMAC7.html)
SG (1) SG194609A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012159115A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11401344B2 (en) 2008-12-01 2022-08-02 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
US20120295259A1 (en) 2011-05-19 2012-11-22 Laboratory Corporation Of America Holdings Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
US10451614B2 (en) 2016-03-15 2019-10-22 Laboratory Corporation Of America Holdings Methods of assessing protein interactions between cells
EP3615067A1 (en) * 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4318846A (en) 1979-09-07 1982-03-09 Syva Company Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
JP2681061B2 (ja) 1988-06-08 1997-11-19 ロンドン・ダイアグノスティック・インコーポレーテッド 検出可能なシグナルのセンシタイザー誘導発生を利用したアッセイ
US4997928A (en) 1988-09-15 1991-03-05 E. I. Du Pont De Nemours And Company Fluorescent reagents for the preparation of 5'-tagged oligonucleotides
US5654442A (en) 1989-11-14 1997-08-05 The Perkin-Elmer Corporation 4,7-dichlorofluorescein dyes as molecular probes
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
ATE146508T1 (de) 1990-11-02 1997-01-15 Zeneca Ltd Polysubstituierte phthalocyanine
JP2758730B2 (ja) 1991-04-25 1998-05-28 三菱電機株式会社 放電励起パルスレーザ発振装置
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5578498A (en) 1991-05-22 1996-11-26 Behringwerke Ag Metal chelate containing compositions for use in chemiluminescent assays
US5340716A (en) 1991-06-20 1994-08-23 Snytex (U.S.A.) Inc. Assay method utilizing photoactivated chemiluminescent label
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
WO1993021230A1 (en) 1992-04-10 1993-10-28 Dana-Farber Cancer Institute, Inc. Activation-state-specific phosphoprotein immunodetection
JP3464798B2 (ja) 1992-07-31 2003-11-10 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 光活性化化学発光基質
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5986076A (en) 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US5945526A (en) 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US6001673A (en) 1999-02-11 1999-12-14 Ericsson Inc. Methods for packaging integrated circuit devices including cavities adjacent active regions
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6673550B2 (en) 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US20030235832A1 (en) 2000-06-21 2003-12-25 Ahmed Chenna Multiplexed analysis by chromatographic separation of molecular tags
US6191278B1 (en) 1999-11-03 2001-02-20 Pe Corporation Water-soluble rhodamine dyes and conjugates thereof
US6372907B1 (en) 1999-11-03 2002-04-16 Apptera Corporation Water-soluble rhodamine dye peptide conjugates
US6346384B1 (en) 2000-03-27 2002-02-12 Dade Behring Inc. Real-time monitoring of PCR using LOCI
US20030170734A1 (en) 2000-04-28 2003-09-11 Stephen Williams Multiplexed assays using electrophoretically separated molecular tags
EP1305632B1 (en) 2000-05-04 2011-07-27 Siemens Healthcare Diagnostics Products GmbH Methods for detection of multiple analytes
WO2003051669A1 (en) 2001-12-18 2003-06-26 Aclara Biosciences, Inc. Photoactivation device and method
EP1478765A4 (en) 2002-03-05 2006-12-06 Aclara Biosciences Inc MULTIPLEX ANALYSIS USING MEMBRANE-FIXED SENSITIZERS
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
ATE442589T1 (de) 2002-07-25 2009-09-15 Aclara Biosciences Inc Nachweis der rezeptoroligomerisierung
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
WO2005011607A2 (en) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
WO2005037071A2 (en) 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
WO2006086730A2 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
EP2438442B1 (en) * 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US20120295259A1 (en) 2011-05-19 2012-11-22 Laboratory Corporation Of America Holdings Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
US20100233732A1 (en) 2009-01-15 2010-09-16 Laboratory Corporation Of America Holdings Methods of Determining Patient Response By Measurement of HER-2 Expression
BRPI1007321A2 (en) * 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
NZ596468A (en) * 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
ES2363669B1 (es) * 2009-06-10 2012-08-09 Fundacio Privada Institut D'investigacio Biomedica De Bellvitge (Idibell) Metodo para determinar el riesgo de desarrollar metastasis cerebral y un kit para llevar a cabo dicho procedimiento
JP5795311B2 (ja) * 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択

Also Published As

Publication number Publication date
JP2014515477A (ja) 2014-06-30
JP2017138334A (ja) 2017-08-10
JP6626037B2 (ja) 2019-12-25
CA2835284C (en) 2020-08-25
JP6468838B2 (ja) 2019-02-13
WO2012159115A1 (en) 2012-11-22
EP3124975B1 (en) 2018-12-05
US20190257836A1 (en) 2019-08-22
CA2835284A1 (en) 2012-11-22
EP2710379A4 (en) 2015-04-08
EP2710379A1 (en) 2014-03-26
US11579148B2 (en) 2023-02-14
US20120295259A1 (en) 2012-11-22
SG194609A1 (en) 2013-12-30
EP2710379B1 (en) 2016-12-14
ES2701929T3 (es) 2019-02-26
EP3124975A1 (en) 2017-02-01

Similar Documents

Publication Publication Date Title
ES2526519T3 (es) Métodos de determinación de la respuesta del paciente por medición de la expresión HER-2
CA2711843C (en) Her-2 diagnostic methods
ES2637411T3 (es) Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
US20160041171A1 (en) Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
CN108780089B (zh) 评估细胞间的蛋白质相互作用的方法
US20130216523A1 (en) Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression
US11579148B2 (en) Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
US20260125490A1 (en) Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients